# A Trial of TQB2868 Plus Platinum-based Chemotherapy With or Without Bevacizumab in the First-line Treatment of Persistent, Recurrent, or Metastatic Cervical Cancer

> **NCT05998941** · PHASE2 · WITHDRAWN · sponsor: **Chia Tai Tianqing Pharmaceutical Group Co., Ltd.**

## Conditions studied

- Cervical Cancer

## Interventions

- **DRUG:** TQB2868 injection
- **DRUG:** Paclitaxel injection
- **DRUG:** Cisplatin injection
- **DRUG:** Carboplatin injection
- **DRUG:** Bevacizumab injection

## Key facts

- **NCT ID:** NCT05998941
- **Lead sponsor:** Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2023-08
- **Primary completion:** 2025-02
- **Final completion:** 2025-06
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Slow progress in development, the sponsor decided to withdraw and no longer proceed.
- **Last updated:** 2023-11-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05998941

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05998941, "A Trial of TQB2868 Plus Platinum-based Chemotherapy With or Without Bevacizumab in the First-line Treatment of Persistent, Recurrent, or Metastatic Cervical Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05998941. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*